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ABSTRACT 
Background and Objectives: Infertility is a distressing problem for couples 
seeking to have children. Hyperprolactinemia is one of the causes of female 
infertility which in itself is caused by a variety of conditions and factors.  
The objective was to investigate hyperprolactinemia in infertile Sudanese 
females and how other related hormones namely gonadotropins and estrogen 
interact in such a condition. The study also aimed to throw some light on the 
interplay of environmental, genetical and physiological factors.  
Materials and Methods: Seventy infertile hyperprolactinemic females 
patients were selected from 385 patients visiting the Reproductive Health 
Care Centre in Khartum. The investigations were carried out to estimate 
prolactin (PRL), follicle stimulating hormone (FSH), luetinizing hormone 
(LH) and estradiol (E2). High sensitive and highly specific enzyme immuno-
assay techniques were used for hormone determinations. 
A structured questionnaire was designed to shed light on the interplay and or 
the effect of environmental, genetical and some pathological conditions with 
respect to hyperprolactinemia and associated infertlty. 
Results: Infertile females were found to have high levels of prolactin ranging 
between 600- 1800 mIU/L and accordingly placed into three categories. 
These were Group 1(G1) with moderately high (670.07 + 10.4), Group2 
(G2) with high (959.0 + 27.5) and Group3 (G3) with very high (1679.7 + 
95.1) prolactin levels, all of which were significantly high when compared to 
the control (146.93 + 21.6); P=0.001 for G1and G2 and P=0.0001 G3. The 
mean values of FSH(G1 12.81± 0.8, G2 11± 0.16, G3 8± 0.14) and LH (G1 
 ix
8.92 ± 1.09, G2 8.45 ± 0.98, G3 6.5 ± 0.87)of the three groups were 
compared with mean values of FSH( 14.15± 1  ) and LH(  10.33± 0.45 ) in 
the control group. A consistent drop,  in the levels of both FSH and LH with 
increasing degree of hyperprolactinemia is observed. The drop is not 
significant for infertile females in G1 with moderately high prolactin level. 
However, it is significant (P< .01) for  G2 and G3 whose hyperprolactinemia 
is almost equal to or over 1000 mlIU/L.  
Checking the estrogen level (2.2433 + 0.06) in these patients showed a  
highly significant (P< 0.001) reduction in its levels when compared to 
control (29.2 + 3.0). Investigation of menstrual cycle patterns in 
hyperprolactinemic patients revealed three classes: patients with 
regular(RC), irregular cycles (IC) and those who suffered amenorrhea (AM). 
The amenorrheaic patients showed the highest levels of PRL (1412.6 + 9.7) 
when compared to control (146.93± 21.6) and their gonadotroins (FSH 
=18.36 + 2.8, LH =16.60 + 2.0) were significantly increased compared to 
controls (FSH  14.15± 1,  LH   10.33± 0.7  ) 
Questionnaire data analysis showed that hyperprolactinemic patients were 
mostly from Central (Sinar, White Nile and Gezira region + khartoum) 
Sudan; 57%  and Northern Sudan were 23%.  
From close relative incidences it was found that 25% of the patients had 
close relatives with infertility problems. 8.57% of the hyperprolactinemic 
infertile females suffered hypothyroidism and were on medication to treat 
hypothyrodism, 2.86% were hypertensive using  antihypertensive drugs and 
no diabetic cases.  
Discussion and Conclusion: It is concluded that the problem of  
hyperprolactinemia is one of the causes of infertility in Sudan. The condition 
 x
is a very complex one that can be caused and affected by hormonal, 
environmental and genetical factors.   
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  ﺍﻷﻃﺮﻭﺣﺔﻣﻠﺨﺺ 
  
ﻋﺪﻡ ﺍﳋﺼﻮﺑﺔ ﻣﺸﻜﻠﺔ ﻣﺆﺭﻗﺔ ﻟﻸﺯﻭﺍﺝ ﺍﻟﺬﻳﻦ ﻳﺴﻌﻮﻥ ﻟﻺﳒﺎﺏ ، ﻓﺮﻁ ﺇﻓﺮﺍﺯ ﺑﺮﻭﻻﻛﺘﲔ : ﺍﳌﻘﺪﻣﺔ ﻭﺍﻻﻫﺪﺍﻑ 
  .ﻭ ﻫﻮ ﻧﻔﺴﻪ ﺗﺴﺒﺒﻪ ﻇﺮﻭﻑ ﻭ ﻋﻮﺍﻣﻞ ﻣﺘﻨﻮﻋﺔ. ﺍﻟﺪﻡ ﻫﻮ ﺃﺣﺪ ﻣﺴﺒﺒﺎﺕ ﻋﺪﻡ ﺍﳋﺼﻮﺑﺔ ﻫﺬﻩ  ﻟﺪﻯ ﺍﻹﻧﺎﺙ 
ﳋﺼﻮﺑﺔ ، ﻭ ﻣﻌﺮﻓﺔ ﻛﻴﻔﻴـﺔ ﻭ ﻗﺪ ﻛﺎﻥ ﺍﳍﺪﻑ ﻫﻮ ﲝﺚ ﻭ ﺩﺭﺍﺳﺔ ﺣﺎﻻﺕ ﻧﺴﺎﺀ ﺳﻮﺩﺍﻧﻴﺎﺕ ﻣﺼﺎﺑﺎﺕ ﺑﻌﺪﻡ ﺍ 
  .ﺗﻔﺎﻋﻞ ﺑﻌﺾ ﺍﳍﺮﻣﻮﻧﺎﺕ ﺍﻷﺧﺮﻯ ﺫﺍﺕ ﺍﻟﻌﻼﻗﺔ  ﻛﺎﻟﻔﻮﻧﺎﺩﻭﺗﺮﻭﺑﲔ ﻭ ﺍﻹﺳﺘﺮﻭﺟﲔ ﰲ ﻫﺬﻩ ﺍﳊﺎﻟﺔ
ﻛﻤﺎ ﻫﺪﻓﺖ ﺍﻟﺪﺭﺍﺳﺔ ﺇﱃ ﺗﺴﻠﻴﻂ ﺑﻌﺾ ﺍﻟﻀﻮﺀ ﻋﻠﻰ ﺗﻀﺎﻓﺮ ﺍﻟﻌﻮﺍﻣﻞ ﺍﻟﺒﻴﺌﻴـﺔ ﻭ ﺍﻟﻮﺭﺍﺛﻴـﺔ ﻭ ﺍﻟﻔـﺴﻴﻮﻟﻮﺟﻴﺔ 
  .ﻭﺍﳌﺮﺿﻴﺔ
 ﻣﻦ ﺍﻟﻨﺴﺎﺀ ﺍﻟﻼﺋﻲ ﻳﻌﺎﻧﲔ ﻣﻦ  ﻋﺪﻡ ﺍﳋﺼﻮﺑﺔ ﻣﻊ  ﰲ ﻫﺬﻩ ﺍﻟﺪﺭﺍﺳﺔ ﰎ ﺇﺧﻀﺎﻉ ﻋﺪﺩ ﺳﺒﻌﲔ :ﺍﳌﻮﺍﺩ ﻭﺍﻟﻨﻈﺮﻳﺎﺕ 
 ﺍﻷﻣﻮﻣـﺔ  ﻣﺮﻳﻀﺔ ﺯﺭﻥ ﺍﳌﺮﻛﺰ ﺍﻻﺳﺘﺸﺎﺭﻱ ﻟـﺼﺤﺔ 583ﻠﺪﺭﺍﺳﺔ  ﺍﺧﺘﺮﻥ ﻣﻦ ﺑﲔ ﺍﻟﱪﻭﻻﻛﺘﲔ ﻟ ﻓﺮﻁ ﺇﻓﺮﺍﺯ 
  ﻭﺍﻟﻄﻔﻮﻟﺔ ﻭﺍﻃﻔﺎﻝ ﺍﻻﻧﺎﺑﻴﺐ
 ﻭ ﻫﺮﻣﻮﻥ (HSF )ﻟﻘﺪ ﰎ ﲢﺪﻳﺪ ﻫﺮﻣﻮﻧﺎﺕ ﺍﻟﱪﻭﻻﻛﺘﲔ ﻭ ﺍﳍﺮﻣﻮﻧﺎﺕ ﺍﻟﺘﻜﺎﺛﺮﻳﺔ ، ﺍﳍﺮﻣﻮﻥ ﺍﳊﻮﺻﻠﻲ ﺍﳌﻨﺒﻪ 
ﺑﺎﺳـﺘﺨﺪﺍﻡ ﺃﺳـﻠﻮﺏ  ﻋـﺎﱄ  ﺩﻳﻮﻝ ﰲ ﺍﻟﻨﺴﺎﺀ ﺍﳌﺼﺎﺑﺎﺕ ﺑﻌﺪﻡ ﺍﳋﺼﻮﺑﺔ ﺍ ﻭ ﺍﻹﺳﺘﺮ (HL) ﺍﻷﺻﻔﺮ ﺍﳉﺴﻢ
   .ﺍﳊﺴﺎﺳﻴﺔ ﻭ ﺍﻟﺘﺨﺼﻴﺺ ﻟﻠﻤﻘﺎﻳﺴﺔ ﺍﳌﻨﺎﻋﻴﺔ ﻟﻺﻧﺰﳝﺎﺕ
ﺍﻹﻧﺎﺙ ﺍﳌﺼﺎﺑﺎﺕ ﺑﻌﺪﻡ ﺍﳋﺼﻮﺑﺔ ﻭ ﺍﻟﻼﺋﻲ ﻳﻌﺎﻧﲔ ﻣﻦ ﻓﺮﻁ ﺇﻓﺮﺍﺯ ﻫﺮﻣﻮﻥ ﺍﻟـﱪﻭﻻﻛﺘﲔ ﰲ ﻭﺿﻌﺖ : ﺍﻟﻨﺘﺎﺋﺞ
 ﻭ (4.01 ±70.076 )ﻣﻌﺘـﺪﻝ ﺍﻻﺭﺗﻔـﺎﻉ : ﺍﻟﱪﻭﻻﻛﺘﲔ ﳎﻤﻮﻋﺎﺕ ﺛﻼﺙ ﺣﺴﺐ ﻣﺴﺘﻮﻳﺎﺕ  ﰲ ﺍﻟﺪﻡ 
ﻣﻘﺎﺭﻧـﺔ ﲟﺠﻤﻮﻋـﺔ ( 1.59 ±7.9761) ً ﻭ ﻋﺎﱄ ﺍﻻﺭﺗﻔﺎﻉ ﺟﺪﺍ (5.72±0.959 )ﻋﺎﱄ ﺍﻻﺭﺗﻔﺎﻉ 
 ﻣﺴﺘﻮﻳﺎﺕ ﻛﻞﱟ ﻣﻦ ﺍﳍﺮﻣﻮﻥ ﺍﳊﻮﺻﻠﻲ ﺍﳌﻨﺒﻪ ﻭ  ﻭ ﰲ ﻛﻞ ﺍﻤﻮﻋﺎﺕ ﻛﺎﻧﺖ (.6.12±29.641)ﺍﻟﺘﺤﻜﻢ 
 ﺍﳍﺮﻣـﻮﻥ ﺍﳊﻮﺻـﻠﻲ ﺍﳌﻨﺒـﻪ ﰲ ﺍﻤﻮﻋـﺔ ﺍﻻﻭﱃ ﻫﺮﻣﻮﻥ ﺍﳉﺴﻢ ﺍﻷﺻﻔﺮ  ﻣﻨﺨﻔﻀﺔ ﺑﺼﻮﺭﺓ ﻣﻠﺤﻮﻇـﺔ 
ﻫﺮﻣﻮﻥ ﺍﳉـﺴﻢ ( . 41.0±8)ﻭﺍﻤﻮﻋﺔ ﺍﻟﺜﺎﻟﺜﺔ ( 61.0±11)ﻭﺍﻤﻮﻋﺔ ﺍﻟﺜﺎﻧﻴﺔ ( 78.0±18.21)
ﻭﺍﻤﻮﻋـﺔ ﺍﻟﺜﺎﻟﺜـﺔ ( 89.0±54.8)ﻭﺍﻤﻮﻋﺔ ﺍﻟﺜﺎﻧﻴـﺔ ( 90.1±29.8)ﺍﻻﺻﻔﺮ ﰲ ﺍﻤﻮﻋﺔ ﺍﻻﻭﱃ 
ﻮﺻـﻠﻲ ﺍﳌﻨﺒـﻪ ﻟﻠـﻬﺮﻣﻮﻥ ﺍﳊ ( 1±51.41) ﺍﻟﱵ ﻛﺎﻧﺖ   ﻣﻘﺎﺭﻧﺔﹰ ﲟﺠﻤﻮﻋﺎﺕ ﺍﻟﺘﺤﻜﻢ (78.0±5.6)
  . ﳍﺮﻣﻮﻥ ﺍﳉﺴﻢ ﺍﻻﺻﻔﺮ ( 54.0±33.01)ﻭ
 . (6.0±3342.2 ) ، ﻭﺟﺪ ﻫﺒﻮﻁ ﻭﺍﺿﺢ  ﰲ ﻣﺴﺘﻮﻳﺎﺗﻪﻨﺪ ﻣﺮﺍﺟﻌﺔ ﻣﺴﺘﻮﻯ ﺍﻻﺳﺘﺮﻭﺟﲔ ﻟﺪﻯ ﺑﻌﻀﻬﻦ ﻋ
  ( .3.0±02.92)ﻣﻘﺎﺭﻧﺔ ﲟﺠﻤﻮﻋﺎﺕ ﺍﻟﺘﺤﻜﻢ 
ﻳﻌﺎﻧﲔ ﻣﻦ ﻋﺪﻡ ﺍﳋﺼﻮﺑﺔ ﻛﺬﻟﻚ ﻟﻠﻜﺸﻒ ﻋﻦ ﻛﻴﻔﻴﺔ ﺗﺄﺛﲑ ﻓﺮﻁ ﺇﻓﺮﺍﺯ ﺑـﺮﻭﻻﻛﺘﲔ ﰎ ﻓﺤﺺ ﺍﻟﻨﺴﺎﺀ ﺍﻟﻼﺋﻲ 
ﳎﻤﻮﻋـﺔ ﻣﻨﺘﻈﻤـﺔ : ﰲ ﳎﻤﻮﻋﺎﺕ ﺛﻼﺙ ﰎ ﻭﺿﻌﻬﻦ  ﻭﻓﻘﺎﹰ ﻟﺬﻟﻚ ﻓﻘﺪ ﺍﻟﺪﻡ ﰲ ﺃﻧﻈﻤﺔ ﺩﻭﺭﺍﻦ ﺍﻟﺸﻬﺮﻳﺔ ، ﻭ 
iix 
ﳎﻤﻮﻋﺔ ﺍﻧﻘﻄﺎﻉ ﺍﻟـﺪﻭﺭﺓ ﺃﻇﻬﺮﺕ . ﺍﻟﺪﻭﺭﺓ ﻭ ﳎﻤﻮﻋﺔ ﻏﲑ ﻣﻨﺘﻈﻤﺔ ﺍﻟﺪﻭﺭﺓ  ﻭ ﳎﻤﻮﻋﺔ ﻣﻨﻘﻄﻌﺔ ﻋﻨﻬﺎ ﺍﻟﺪﻭﺭﺓ 
 .(6.12±39.641 )ﻣﻘﺎﺭﻧﺔ  ﲟﺠﻤﻮﻋﺎﺕ ﺍﻟﺘﺤﻜﻢ ( 7.9±36.2141)ﻮﻳﺎﺕ ﺍﻟﱪﻭﻻﻛﺘﲔ ﻣﺴﺘﺃﻋﻠﻰ 
( 8.2±63.81)ﻭﻛﺎﻧﺖ ﻫﺮﻣﻮﻧﺎﺕ ﺍﻟﻘﻮﻧﺎﺩﻭﺗﺮﻭﺑﲔ ﻟﺪﻳﻬﻦ ﺯﺍﺋﺪﺓ ﺑﺼﻔﺔ ﻣﻠﺤﻮﻇﺔ ﺍﳍﺮﻣﻮﻥ ﺍﳊﻮﺻﻠﻲ ﺍﳌﻨﺒﻪ 
ﻣﻘﺎﺭﻧـﺔ ﲟﺠﻤﻮﻋـﺎﺕ ﺍﻟـﺘﺤﻜﻢ ﻟﻠـﻬﺮﻣﻮﻥ ﺍﳊﻮﺻـﻠﻲ ﺍﳌﻨﺒـﻪ ( 2±6.61)ﻭﻫﺮﻣﻮﻥ ﺍﳉﺴﻢ ﺍﻻﺻﻔﺮ 
  (7.0±33.1)ﻭﳍﺮﻣﻮﻥ ﺍﳉﺴﻢ ﺍﻻﺻﻔﺮ ( 1±51.41)
 ﺍﻟﺪﻡ ﻛﻦ ﻣـﻦ ﻭﺳـﻂ ﻭ ﻗﺪ ﺃﻇﻬﺮ ﲢﻠﻴﻞ ﺑﻴﺎﻧﺎﺕ ﺍﻻﺳﺘﺒﻴﺎﻥ ﺃﻥ ﺍﻟﻨﺴﺎﺀ ﺍﻟﻼﺋﻲ ﻳﻌﺎﻧﲔ ﻓﺮﻁ ﺇﻓﺮﺍﺯ ﺑﺮﻭﻻﻛﺘﲔ 
ﻣﻦ ﺑﲔ ﻣﺴﺒﺒﺎﺕ ﻓﺮﻁ  ﻛﺎﻥ ﻮﺭﺍﺛﻲﺍﻟﻌﺎﻣﻞ ﺍﻟ،  %(75 ) ﻭﺍﳋﺮﻃﻮﻡ ( ﺍﳉﺰﻳﺮﺓ - ﺍﻟﻨﻴﻞ ﺍﻻﺑﻴﺾ -ﺳﻨﺎﺭ )ﺍﻟﺴﻮﺩﺍﻥ
ﺔ ﺍﺳﺘﺨﺪﺍﻡ ﻋﻘﺎﻗﲑ ﺍﺭﺗﻔﺎﻉ ﺿﻐﻂ ﺍﻟﺪﻡ ﻭ ﻣﻌﺎﳉ  ـﰲ ﻳﻌﺾ ﺍﳌﺮﻳﻀﺎﺕ ﻳﺒﺪﻭ ﺃﻥ . %52 ﺇﻓﺮﺍﺯ ﺑﺮﻭﻻﻛﺘﲔ ﺍﻟﺪﻡ 
  . ﺍﳌﺴﺒﺒﺎﺕﺓ ﺍﻟﺪﺭﻗﻴﺔ ﻗﺪ ﺗﻜﻮﻥ ﺃﺣﺪﺍﳌﺼﺎﺑﺎﺕ ﺑﺎﻟﻐﺪ
ﻣﻨـﻬﺎ ﺗـﺄﺛﲑ  ﻡ ﺍﻻﺧﺼﺎﺏ ﻣﻌﻘﺪﺓ ﻭﺗﺴﺒﺒﻬﺎ ﻋﺪﺓ ﻋﻮﺍﻣﻞ  ﻋﺪ ﻣﺸﻜﻠﺔﻗﺪ ﺗﻮﺻﻠﺖ ﺍﻟﺪﺭﺍﺳﺔ ﺇﱃ ﺃﻥ : ﺍﳋﻼﺻﺔ
  .ﺍﳍﺮﻣﻮﻧﺎﺕ ﻭﺍﻟﺒﻴﺌﺔ ﻭﺍﻟﻌﻮﺍﻣﻞ ﺍﻟﻮﺭﺍﺛﻴﺔ 
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Introduction 
Throughout the world, millions of couples suffer involuntarily from  
infertility, and this causes a variety of personal and social problems.  
Infertility in general, would appear to affect 5 – 15 % of couples of the 
reproductive age group of the word’s population. This percentage represents 
35 – 105 million couples of which 10 – 20 % will be infertile without a 
cause being identified (WHO. 1984). 
Infertility is defined as the inability to conceive after more than one year of 
unprotected intercourse (WHO. 1975). It is considered as primary when 
there is no history of a pervious pregnancy and secondary when the female 
has previously become pregnant, but cannot achieve a new gestation 
(Acosta, and Nieves, 1988).  
Traditionally in past times, the female has been considered as the prime 
cause of barren marriages. However, over time the concept of a "male 
factor" has emerged, and now male infertility is widely recognized. 
According to current data, about one third of cases of infertility are 
attributable to male factors, one third to female factors, and one third to both 
male and female factors (Baum 1988). 
Data from the world fertility surveys suggest that the percentage of infertile 
couples as well as the prevalence of its different causes varies from one 
country to another and among different countries (WHO. 1984). The 
variation in the levels and patterns of infertility and the relationship between 
them depends on the interplay between "core" fertility that includes 
chromosomal, congenital, and hormonal abnormalities, and "acquired" 
infertility due to infections as well as environmental and occupational 
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factors (Mohamed 1992). Among these hormonal abnormalities is primarily 
targeted for purposes of diagnosis and management. Hormonal abnormalities 
include an array of irregularities of endocrine functions of the pituitary and 
the gonads affecting levels of follicle stimulating hormone (FSH), 
leutinizing hormone (LH), prolactin, estrogen and progesterone. Other 
hormonal anamolies may involve the thyroid gland. 
 
objectives:  
The basic objectives of this study will be the following:- 
1- To in evaluate the significance and prevalence of 
hyperprolactinemia in Sudanese female patient’s infertility. 
2-  To investigate the relationship between prolactin, FSH, LH 
and oestradiol.  
3- To assess the predominant cause and look into curability of 
the disorder. 
4- To study the menstrual patterns in hyperprolactinic infertility 
Sudanese females.  
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Chapter one 
 Literature Review 
1.1. Prolactin: 
Prolactin (PRL) is a polypeptide hormone secreted by the anterior pituitary gland, 
whose main role is to stimulate lactation in the postpartum period. Increases in 
prolactin secretion can be physiological (pregnancy and lactation) or pathological 
(hypothalamic and pituitary disease). The suppression of the hypothalamic- 
pituitary-gonadal axis and the resistance of the ovary to gonadotropin action are 
induced in hyperprolactinemia resulting in amenorrhea and lack of ovulation. 
Infertility associated with hyperprolactinemia in females can be reversed with 
treatment. A recent progress in female sterility reported that the ovulatory 
disturbances occupy the second position of the female sterile factor (Loneseu et 
al. 2002 ). The precise endocrinological examination must be done for the 
diagnosis of the ovulatory disturbances. Generally clomiphene citrate is used for 
moderate hypothalamic anovulations, and bromocriptine is for prolactin related 
diseases and endocrinological polycyctic ovary (Aisake 1997).  
1.1.1. Prolactin structure: 
Human prolactin consists of 199 amino acids and has three intramolecular 
disulfide bonds. Prolactin circulates in the blood predominantly in a monomeric 
form (23 kd) but it also exists in a dimeric (48 to 56 kd) and polymeric (> 100 kd) 
forms (Wilson et al. 1998). Although the major form of prolactin found in the 
pituitary gland is 23 kd, variants of prolactin have been characterized in many 
mammals, including humans. Prolactin variants can be results of alternative 
splicing of the primary transcript, proteolytic cleavage and other posttranslational 
modifications of the amino acid chain. 
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1.1.2. Physiologic Effect of Prolactin:   
Prolactin, the major hormone in lactogenesis, action is modulated by a 
combination of second messenger activities that include cyclic nucleotides, 
prostaglandin, calcium ion changes, polyamine production and growth factors. In 
pregnancy cAMP and cGMP increase progressively and may be involved in 
stimulation of the mitogenic and morphogenic processes that occur with 
pregnancy. At delivery cAMP levels falls precipitously, and cGMP levels 
continue to rise and stay elevated in the lactation period (Peterson 1997).  
Prolactin is best known for the multiple effects it exerts on the mammary gland. 
The varied effects of prolactin on the mammary gland include growth and 
development of the mammary gland (mammogenesis), synthesis of milk 
(lactogenesis), and maintenance of milk secretion (galactopoiesis). Although it 
has long been accepted that prolactin is involved in the development of the 
mammary gland (Bern and Nicoll 1968), recent elegant techniques have 
confirmed such findings. Targeted disruption of the prolactin gene (prolactin 
knockout) (Horseman et al.1997) or knockout of the prolactin receptor (Ormandy 
et al., 1997) results in abnormal mammogenesis characterized by complete 
absence of lobuloalveolar units in adult homozygous females. Prolactin knockout 
heterozygotes appear to have nearly normal mammogenesis that is 
indistinguishable from wild type (Horseman et a.l 1997). 
However, it also exerts effects on other targets important to the reproduction of 
the mammalian species. In some mammals, particularly rodents, prolactin is also 
important for the maintenance and secretory activity of the corpus luteum. It also 
affects other actions related to reproduction such as mating and maternal 
behaviors.  
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Lactogenesis clearly requires pituitary prolactin, since hypophysectomy during 
pregnancy prevents subsequent lactation (Nelson and Gaunt 1936). In the process 
of lactogenesis, prolactin stimulates uptake of some amino acids, the synthesis of 
the milk proteins casein and -lactalbumin, uptake of glucose, and synthesis of the 
milk sugar lactose as well as milk fats (Bar ber  et al., 1992; Tuker 1994)  
Actions of prolactin on luteal function depend on species and the stage of the 
estrous cycle. In rodents, prolactin can either be luteotrophic after mating or 
luteolytic in the absence of a mating stimulus. 
In most rodents, prolactin acts as a luteotrophic hormone by maintaining the 
structural and functional integrity of the corpus luteum for 6 days after mating 
(Morishige and Rothchild 1974). This "luteotrophic" action of prolactin, which 
has been best described in the rat, is characterized by enhanced progesterone 
secretion . Progesterone is essential for the implantation of the fertilized ovum 
(along with estrogen), maintenance of pregnancy, and inhibition of ovulation 
(Freeman 1994).  
Prolactin enhances progesterone secretion two ways: prolactin potentiates the 
steroidogenic effects of luteinizing hormone (LH) in granulosa-luteal cells 
(Richards and Williams 1967) and inhibits the 20-hydroxysteroid dehydrogenase 
enzyme, which inactivates progesterone (Freeman 1994). 
1.1.3. Regulation of Prolactin Secretion: 
Prolactin, like all anterior pituitary hormones is secreted in an episodic 
manner((Wilson 1998). Plasma concentrations of prolactin are the highest during 
sleep and the lowest during the waking hours in humans (Parker et al., 1974; 
Sassin et al., 1973). Recent human volunteer experiments proved, however, that 
this rhythm of prolactin secretion is maintained in a constant environment 
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independent of the rhythm of sleep (Waldstreisher 1996) although with 
considerably larger amplitude in women than men. The best-known physiological 
stimulus affecting prolactin secretion is the suckling stimulus applied by the 
nursing young. Cessation of the suckling stimulus results in termination of 
prolactin secretion, and the rate of decrease in blood prolactin levels is 
proportional to the metabolic clearance rate of the hormone (Grosvenor et al., 
1979 ;Nagy and Halasz 1983) Moreover, the amount of prolactin released is 
related to the intensity of the stimulus. In humans (Diaz et al., 1989 ; Stern and 
Rechlin 1990) and cattle (Lefcourt et al.,1994) the prolactin-secretory response to 
nursing is superimposed by the endogenous circadian rhythm of prolactin 
secretion; that is, the same intensity of suckling stimulus can elevate prolactin 
levels more effectively at certain times of day when the circadian input enhances 
the suckling stimulus-evoked secretory response. 
Hypothalamic control of the preovulatory proestrous surge of prolactin is far 
from clear. Although it is clear that dopamine inhibits prolactin secretion and that 
removal of the tonic dopaminergic inhibition results in enhanced prolactin 
secretion, the role of dopamine as a regulator of the proestrous surge of prolactin 
is contradictory. 
Its secretion is enhanced by various prolactin releasing factors (Wilson et al., 
1998).  
It is clear that prolactin secretion is dramatically affected by "stress." A myriad of 
stresses have been used to characterize such effects on prolactin secretion. These 
include, but are not limited to, the following: ether stress (Bank et al., 1994; 
Grattan and Waverill1991; Johnston and Negro-Vilar1986; Kaji et al., 1985; 
Lookingland, et al., 1990; Muri and Ben-Jonathan 1987; Neill 1970; (Yogev et 
al., 1994; restraint stress Demarest et al., 1984; Gala and Haisenlder 1986; 
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Jurcovicova et al., 1990; Kehoe et al., 1991; Ramalho et al.,1995; thermal stress 
Vaha-Eskeli et al., 1991; hemorrhage Burns and Sarkar 1993;  Jurcovicova  et al., 
1990; social conflict Haisenleder  et al., 1986) and even academic stress in 
humans (Malarkey et al., 1991). 
Because, in most cases, the prolactin-secretory response (i.e., stimulation or 
inhibition) differs depending on the nature of stress, one cannot describe a unitary 
mechanism but must define the mechanism associated with each specific stress 
modality. 
The most important physiological stimuli that elevate pituitary prolactin secretion 
are suckling (Neill 1974; Terkel et al.1972; stress Neill 1970 and increased levels 
of ovarian steroids, primarily estrogen Neill 1970; Nill  e ta,l 1982). Such stimuli 
are transduced by the hypothalamus which elaborates a host of PRF and 
prolactin-inhibiting factors (PIF) (Fig. 2). In mammals, the control exerted by the 
hypothalamus over pituitary prolactin secretion is largely inhibitory (Ben-
Jonathan1985). On the other hand, the hypothalamus is also involved in the acute 
stimulatory control of prolactin secretion by removal of the inhibition 
(disinhibition) and/or superimposition of brief stimulatory input. In addition, 
prolactin secretion is also influenced by numerous factors released by the 
lactotrophs themselves (autocrine regulation) or by other cells within the pituitary 
gland (paracrine regulation).  
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1.2. Hyperprolactinemia:   
 
Hyperprolactinemia means  the presence of abnormally high levels of prolactin in 
the circulation(Haslett et al.,2002) Normal levels are less than 580 mIU/L for 
women, and less than 450 mIU/L for men. It is the most common clinical 
hypothalamic-hypophysis disorder. Sexual dysfunction in women with 
hyperprolactinemia is not uncommon. A significant percent of women with 
evaluated hyperprolactinemia had sexual dysfunction (Kadioglu et al.,2005).  
European investigators have measured prolactin levels in females presenting with 
abnormalities of the menstrual cycle and have reported a 15-30 % incidence of 
hyperprolactinemia (Seppala, et al.,1975). Their data confirm this finding and 
suggest that many women suffering from oligomenrrhea or secondary 
amenorrhea may suffer from a disorder of prolactin secretion. 
1.2.1.  Consequences of  hyperprolactinemia: 
An excess of prolactin can suppress ovulation and can be symptomatic of 
hypothyroidism or luteal phase defects. In women, symptoms of this condition 
include galactorrhea (the production of breast milk by non-nursing women) and 
anovulation (when a woman does not ovulate). 
Of greater concern, however, is that this abnormality of prolactin is associated 
with an absence of cyclic gonadotropin  secretion (Tyeson, et al.,1948) resulting 
in menses cessation, amenorrhea which can be primary or secondary.  
Primary amenorrhea can be diagnosed if a patient has normal secondary sexual 
characteristics but no menarche by 16 years of age. If a patient has no 
secondary sexual characteristics and no menarche, primary amenorrhea can be 
diagnosed as early as 14 years of age. Secondary amenorrhea is the absence of 
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menses for three months in women with previously normal menstruation and 
for nine months in women with previous oligomenorrhea. Secondary 
amenorrhea is more common than primary amenorrhea (The Practice 
Committee of the American Society For Reproductive Medicine 2004; 
Speroff,L. and Fritz 2005). 
Although amenorrhea and anovulation are the most usual clinical findings but 
other alterations of gonadal function as oligomenorrhea or luteal phase alterations 
can be found. Galactorrhea appears in approximately 30 % of patients, but its 
presence in women with ovulation disorders is highly suggestive of 
hyperprolactinemia (Rosaro and Garofalo 2002). The action of PRL in supra-
physiological levels on the ovaries or on the hypothalamic-pituitary axis for the 
release of gonadotropins leads to inhibition of the cyclic functioning of the 
pituitary gland and of the ovaries. The consequences are either the production of 
immature follicles marked by anovulatory or dysovulatory cycles, or absence of 
follicle production marked by amenorrhea. Thus, prolactin plays a major role in 
the reproductive system not only by its lactotropic but also by its 
antigonadotropic effects (Bessioud, et al.2002). The relationship between 
elevated prolactin levels and menstrual cycle in infertile Sudanese females was 
studied and the results showed that 36 % of regularly menstruating infertile 
Sudanese were hyperprolactinaemic. The incidence of hyperprolactinemia among 
oligomenorrhoeic group was reported to be 20% (5). 
When menarche has failed to occur or menstrual cycle have stopped, the problem 
can be traced back to a functional or structural defect in the hypothalamus, 
pituitary, ovaries, or uterus (Norrison 1998). 
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Subjects with primary amenorrhea and delayed puberty can present with 
hyperprolactinemia (Rosaro and Garofalo, 2002). Primary amenorrhea caused by 
hyperprolactinemia is a rare condition. Bromocriptine therapy, however, proved 
useful in inducing ovulation and cause the menarche onset (Kawano.et al.,2000).  
Increased prolactin levels will lead to decreased bone density when compared 
with healthy individuals of the same age. The longer someone has 
hyperprolactinemia, the lower the bone mass will become. The more abnormal 
menstrual function is, the lower the bone density (Hergenroeder 1995). 
 
1.2.2 Causes of hyperprolactinemia: 
Hyperprolactinemia can be caused by several factors such as: 
1.2.2.1  Tumors of the pituitary gland: 
Prolactinomas are the most common pituitary tumors (Hattori 2003; Biller 1999). 
Prolactinomas  represent a 60 % of pituitary tumors with various symptoms, 
hormonal and reproductive abnormalities. It has been pointed that prolactinomas 
prevailed among females in reproductive age with a higher incidence of 
macroadenoma.  The most common alterations related to reproductive tract seen 
were menstrual irregularities, galactorrhea, infertility, hyperprolactinemia, 
hypogonadism and abnormalities of puberty (Hurtado et al.,,2004). 
 
1.2.2.2. Thyroid gland disorder: 
The hyperprolactinemia of hypothyroidism is related to several mechanisms. In 
response to the hypothyroid state, a compensatory increase in the discharge of 
central hypothalamic thyrotropin-releasing hormone results in increased 
 9
stimulation of prolactin secretion. Furthermore, prolactin elimination from the 
systemic circulation is reduced, which contributes to increased prolactin 
concentrations.(Asa and Ezzat 2002). 
1.2.2.3. Drugs: 
Drugs that block the effects of dopamine at the pituitary or deplete dopamine 
stores in the brain may cause the pituitary to secrete prolactin. These drugs 
include the major tranquilizers, high blood pressure medications, and antinausea 
drugs. Oral contraceptives and recreational drugs (such as marijuana) 
1.2.2.4.  Macroprolactinemia:  
Patients with macroprolactinaemia are clinically characterized by the lack of 
amenorrhea and galactorrhea ie asymptomatic with intact gonadal and 
reproductive function and pregnancy was possible despite a marked 
hyperprolactinemia (Hattori 2003).  This term should not be confused with 
macroprolactinoma, which refers to a large pituitary tumour greater than 10 mm 
in diameter. Macroprolactinemia refers to a polymeric form of prolactin in which 
several prolactin molecules form a polymer that is recognized by 
immunologically based serum assays. In general, macroprolactin results from the 
binding of prolactin to IgG antibodies. The large prolactin polymer is unable to 
interact with the prolactin receptor. Little, if any, biological effect of prolactin 
excess is noted(Vallette-Kasic et al., 2002). It was found that anti-PRL 
autoantibody is the leading cause of macroprolactinemia that might be 
heterogeneous in nature.  
1.2.3.  Hyperprolactinemia in female infertility:   
A prospective study was undertaken to determine the incidence of 
hyperprolactinemia in a group of referred infertile females. Of 133 referred 
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infertility patients, 19.5% had elevated levels of serum prolactin. 4.4% patients 
with hyperprolactinemia had neither abnormal menstrual function nor 
galactorrhea. Hyperprolactinemia is a common finding in an infertile population, 
more so when galactorrhea and / or menstrual dysfunction is also present 
(Kredentser et al.,1981). 
 
1.2.4. Hyperprolactinemia in Polycystic Ovary Syndrome:  
The polycystic ovary (PCO) results from a systemic hormonal dysfunction 
(Gonzalez et al., 2003). With the use of multiple blood sampling, the prevalence 
of hyperprolactinemia, in 150 patients with polycystic ovary syndrome was found 
to be 17% (Luciano et al., 1984). The clinical features of PCO may include 
chronic anovulation, hyperandrogenism, and bilaterally enlarged multicytic 
ovaries (Goldzieher 1981). The endocrine profile of patients with (PCO) reflects 
the mild elevations in serum or urinary androgens and normal to elevated serum 
lutenizing hormone (LH) with suppressed follicle stimulating hormone (FSH) 
levels, resulting in an increased LH / FSH ratio (Yen.1980). It was concluded that 
a population with PCO has a higher risk of infertility, anovulation, obesity, 
hyperandrogenism, and abnormal menses.  
 
1.2.5. Psychological distress in patients with hyperprolactinemia: 
It is now recognized that prolactin has effects on behavior. Both prolactin and its 
receptor are found within various regions of the brain (Harlan et al.,,1983; 
Bridges et al.,,1935; Emanuele et al., 1992 and Dutt et al.,1994). In clinical 
settings it has been observed that patients with hyperprolactinemia may display 
psychological symptoms (Fava et al.,1981). It has been found that 
hyperprolactinemic patient reported significant increase in symptom of 
depression, anxiety and hostility (Reavley  et al.,.1997).  
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1.2.6.  Hyperprolactinemia and bone mineral density:   
Studies in women with hyperprolactinemia resulting from pituitary tumors have 
demonstrated high rates of osteoporosis believed to result from hypoestrogenism. 
Preliminary surveys have indicated that schizophrenia patients also may have 
elevated rates of osteoporosis and pathological fractures, possibly resulting in 
part from the long-term administration of antipsychotic agent that produce 
hyperprolactinemia and secondarily low estrogen and testosterone levels. This 
potential complication of treatment with certain antipsychotic agents requires 
careful study and could represent a serious public health problem as the 
schizophrenia prevalence is about 10% worldwide. Such patients are at increased 
risk for osteoporosis because of several reasons including poor diet, lack of 
exercise and excessive smoking (Naildoo et al., 2003). 
 
1.3.  Anovulation:   
Anovulation, a common cause of female infertility, is a curable condition 
(Homburg 2003). The disorder of ovulation accounts for about 30 % of infertility 
and often presents with irregular periods or absence of menses associated with 
hyperprolactinemia. (Fairley and Taylor 2003). 
 
1.4. Gonadotrophic hormones: 
These are two hormones secreted from cells in the anterior pituitary called 
gonadotrophs. Most gonadotrophs secrete only Luteinizing hormone LH also 
called luteotropin or Follicle Stimulating hormone FSH, also called 
folliculotropin but some appear to secrete both hormones. 
 12
1.4.1. Gonadotropin structure:  
As thyroid-simulating hormone, LH and FSH are large glycoproteins composed 
of alpha and beta subunits. The alpha subunit is identical in all three of these 
anterior pituitary hormones, while the beta subunit is unique and endows each 
hormone with the ability to bind its own receptor.  
1.4.2.  Gonadotropin functions: 
FSH is the hormone that stimulates the growth and secretion of ovarian follicle in 
females. LH is responsible for stimulation in females and the conversion of the 
ovulated ovarian follicle into an endocrine structure called a corpus luteum (Fox 
2002).  
1.4.2.1. Luteinizing Hormone 
In both sexes, LH stimulates secretion of sex steroids from the gonads. In the 
testes, LH binds to receptors on Leydig cells, stimulating synthesis and secretion 
of testosterone. In females LH is responsible for stimulation of theca cells in the 
ovary to secrete testosterone, which is converted into estrogen by adjacent 
granulosa cells. Consequently this stimulates conversion of the ovulated ovarian 
follicle into an endocrine structure called a corpus luteum (Demarest et al.,1984). 
which secrete the steroid hormones progesterone. Progesterone is necessary for 
maintenance of pregnancy, and, in most mammals, LH is required for continued 
development and function of corpora lutea. The name luteinizing hormone 
derives from this effect of inducing luteinization of ovarian follicles. 
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1.4.2.2. Follicle-Stimulating Hormone 
As its name implies, FSH stimulates 
the maturation of ovarian follicles.  
Administration of FSH to 
humans and animals induces                                       Fig (1): Preovulatory follicle 
"superovulation", or development of more than the usual number of mature 
follicles and hence, an increased number of mature gametes Fig(1). FSH is also 
critical for sperm production. It supports the function of Sertoli cells, which in 
turn support many aspects of sperm cell maturation.  
1.4.3. Control of Gonadotropin secretion : 
The principle regulator of LH and FSH secretion is gonadotropin-releasing 
hormone (GnRH) also known as LH-releasing hormone. GnRH is a ten amino 
acid peptide that is synthesized and secreted from hypothalamic neurons and 
binds to receptors on gonadotrophs.  
As depicted in the figure(2) below, GnRH stimulates secretion of LH, which in 
turn stimulates gonadal secretion of the sex steroids testosterone, estrogen and 
progesterone. In a classical negative feedback loop, sex steroids inhibit secretion 
of GnRH and also appear to have direct negative effects on gonadotrophs.  
This regulatory loop leads to pulsatile secretion of LH and, to a much lesser 
extent, FSH. The number of pulses of GnRH and LH varies from a few per day to 
one or more per hour. In females, pulse frequency is clearly related to stage of the 
cycle. Numerous hormones influence GnRH secretion, and positive and negative 
control over GnRH and gonadotropin secretion is actually considerably more 
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complex than depicted in the figure. For example, the gonads secrete at least two 
additional hormones; inhibin and activin which selectively inhibit and activate 
FSH secretion from the pituitary 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig (2) : Illustrates the feedback loops that controls the secretion of LH and 
FSH. 
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1.5. Estrogens: 
Three compounds with estrogen activity have been isolated. All are C18 steroids. 
β-Estradiol is the hormone normally secreted by the ovarian follicle. Estrone and 
estriol are largely products of estradiol metabolism. The ovary is the principal 
site of estrogen production in the nonpregnant female. In females estrogens are 
also products of the fetal-placental unit. 
1.5.1. Secretion of Estrogens:         
In adult women during the reproductive years the daily secretion of estrogens 
varies cyclically during the menstrual cycle. Daily secretions of estradiol or 
estrone are 0.1 to 0.2 mg / day at time of ovulation in mid cycle. Estrogen 
secretion is determined by the rate of estrogen synthesis, which is governed by 
the two pituitary gonadotropins LH and FSH. 
1.5.2. Biologic actions of estrogens: 
(a) Reproductive system:- 
Although estrogens affect nearly all vertebrate tissues to some degree, their 
principal effect is stimulation of growth and maturation of organs composing the 
female’s reproductive system and the maintance of its reproductive capacity. 
These include the uterus, vagina, breasts and also influence pattern of pubic and 
axillary hair. In addition there may be local effects exerted within the ovary to 
stimulate growth of follicles, a process normally controlled by the pituitary 
gonadotropins.   
(b) Bone metabolism: 
That estrogens regulate normal bone metabolism is suggested from the bone 
decalcification seen in postmenopausal osteoporosis in the human female. 
Estrogens promote closer of bony epiphyses similar to that of androgens, so that 
girls deficient in estrogens prior to completion of puberty may demonstrate a lack 
of epiphseal closure and grow abnormally tall (Smith et al.,,1983). 
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1.6. The menstrual cycle: 
The normal reproductive years of a female are characterized by monthly 
rhythmical changes in the rates of secretion of the female hormones and 
corresponding changes in the sexual organs themselves. This rhythm is called the 
female sexual cycle or menstrual cycle. The duration of the cycle averages 28 
days, and may be as short as 20 days or as long as 45 days even in completely 
normal females. Abnormal cycle length is often associated with decreased 
fertility. However, the two significant results of the female sexual cycle are: 
1- Only a single ovum is normally released from the ovaries each month, 
so that normally only a single fetus can grow at a time. 
2- The uterine endometrum is prepared for implantation of the fertilized 
ovum at required time of the month.  
The ovarian changes during the sexual cycle are completely dependant on 
gonadotropic hormones secreted by the anterior pituitary. Ovaries that are not 
stimulated by these gonadtropic hormones remain inactive, which is the case 
throughout childhood when almost no gonadotropic hormones are secreted. 
However begins secreting proressivly more and more gandotropic hormones, 
which culminates in the initiation of monthy sexual cycle between the age 11 and 
15 years; this culmination is called menarche. The anterior pituitary secretes two 
different hormones that are known to be essential for function of the ovaries FSH 
and LH during each month of the female sexual cycle, there is a cyclic increase 
and decrease of them as illustrated in figure (3), (Gugton and Hall1997). 
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(From Gyton and Hall 1997) 
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Diagnosis and management of abnormal menstrual function must be based 
upon an understanding of the regulation of the normal cycle. Dynamic 
relationships exist between the hypothalamic, pituitary and gonadal 
hormones which allow for the cyclic nature of the normal female 
reproductive process. These hormonal changes are correlated with 
morphologic changes in the ovary, making the coordination of this system 
one of the most remarkable event in biology (Speroff et al.,.1983). 
The ovarian cycle takes place as a result of the interaction of the central 
nervous system (CNS) and the hypothalamo – hypophysial – ovarian axis. 
The CNS and the hypothalamus constitute the control for the coordinating 
elements which in turn act as signal generators. The hypophysic converts the 
hypothalamic signals to gonado0trophins and the ovaries guarantee the 
cyclical control through feedback mechanism. Alterations in any of the 
normal steps will lead to in fertility as manifested by an ovulation, in 
adequate ovulation or the production of an in sufficient corpus lutcum. The 
disturbance in ovarian function is  
usually, but not always, manifested by an abnormality in the pattern of 
menstruation, e.g. amenorrhea, oligomenorrhea or some variability in 
menstrual cycle length (Baird 1979; De Acosta and Andino1985). 
 
1.7.  Relationship of prolactin and gonadotrophic hormones in 
regulation of the ovarian function:  
Circulating concentration of the LH, FSH, prolactin (PRL), oestrdiol- 17 
beta (E2) were instigated in female with normal cycle and proven fertility, 
with irregular cycles and in fertility and with primary or secondary 
amenorrhea in order to understand the relationship of the prolactin and 
gonadotrophic hormones in regulation of the ovarian function. The results 
indicate that hyperprolactinemia inhibits the pituitary to release the mid 
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cycle LH surge in response to positive feedback action of the elevated 
oestrogen at the mid cycle. The elevated LH and FSH level found in the 
cases of the secondary amenorrhea is the indication of the absence of the 
steroid negative feedback due to the ovarian failure (Khana et al., 1990). 
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CHAPTER TWO  
MATRIALS AND METHODS 
2.1. Materials: 
2.1.1. Study population: 
2.1.1.1.  Human subjects for control experiments  
Fifteen females of proven fertility and in their reproductive age, who were 
not suffering from any systemic endocrine disease, were selected to serve as 
a control group, their age range was 15 – 45 years. 
2.1.1.2. Infertile female subjects: 
a) Three hundred and eighty five infertile females with a medical 
history of primary or secondary infertility were studied. Their ages 
ranged from 15 to 45 years. 
b) Seventy infertile female with a medical history of primary or 
secondary infertility due to hyperprolactinemia were studied. 
c) Thirty five patients were investigated for levels of estradiol . 
2.1.2. Samples: 
A single fasting blood sample was collected from each subject. From all 
patients 5ml. of the venous blood samples were collected in the morning (8ـ  
10a. m.), allowed to clot and immediately centrifuged for 10 minutes and 
stored at - 20°C until analyzed.  
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2.1.3. Equipment: 
i- Photometer: Biosystems BTS – 310 Photometer. 
ii- Pipettes: Manual pipette was used for pipetting samples and standards 
at the beginning of the assay, and automatic pipettes delivering 200µ, 
500µ and 1ml were used for subsequent reagent additions. 
iii-  Vortex mixer: GENIE 2. 
iv- Test tubes with round bottomed 12 ×75mm glass. 
v- Magnetic racks and separators compatible with 12 ×75mm test-tubes. 
vi-  37°C water bath. 
vii- Refrigerator. 
viii- Timer. 
ix-  Various glassware including measuring cylinders, beakers and 
reagent bottles of varring capacities. 
2.1.4.  Reagents: 
2.1.4.1  Reagents for prolactin estimation: 
Prolactin Enzyme Immunoassay (EIA) standards, prolactin EIA Enzyme 
labeled antibody, prolactin EIA magnetic antibody EIA substrate reagent, 
EIA substrate buffer, prolactin EIA assay buffer, prolactin EIA wash buffer, 
EIA stop buffer, prolactin EIA QC sample and De-ionized or distilled water. 
2.1.4.2. Reagent for Follicle Stimulating Hormone (FSH) estimation: 
FSH EIA standards, FSH EIA Enzyme Lapelled Antibody, FSH EIA 
magnetic antibody, EIA substrate reagent, EIA substrate assay buffer, FSH 
EIA assay buffer, FSH EIA wash buffer, EIA stop buffer, FSH EIA QC 
sample and de-ionized or distilled water.   
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2.1.4.3.  Reagents for Luteinising Hormone (LH) estimation: 
LH EIA standards, LH EIA enzyme Labelled Antibody LH EIA magnetic 
labeled Antibody, EIA substrate reagent, EIA substrate Buffer, LH EIA 
wash Buffer, EIA stop Buffer, LH EIA Internal QC sample and De-ionized 
or Distilled water.  
2.1.4.4. Reagents for Estradiol (E2) estimation:   
E2 EIA standards, E2 EIA Antiserum, E2 EIA Enzyme Label, E2 EIA 
separation Reagent, E2 EIA wash concentrate, EIA substrate Reagent, EIA 
substrate Buffer, E2 EIA QC. sample, E2 EIA wash concentrate and Distilled 
water. 
2.2. Methods:    
Estimation of prolactin (PRL), Follicle stimulation Hormone (FSH), 
Leutinizing hormone (LH) and Estradiol (E2) were carried out by 
appropriate Enzyme – linked immuno sorbent assays (sawlat sufi and 
Maggie hayes Immunoneterics UK 2004). 
2.2.1. Prolactin estimation: 
The enzyme immunoassay (EIA) system was developed for the 
measurement of prolactin (PRL) in human serum or plasma. 
The time required to complete an assay is approximately 3 hours. The 
concentration range covered by standards was 0-2400 ml IU/L (WHO IRP 
84 1500) with a minimum detectable dose of approximately 20 ml IU/L by 
immunometrics (UK) Ltd. 
2.2.1.1. Prolactin EIA Assay Procedure:  
(a) Step1 reaction: Immuno extraction of prolactin 
i- 100µl standard or sample were pipetted into test tubes. 
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ii- 100 µl working suspension of prolactin EIA Magnetic Antibody were 
added at room temperature by using a 100µl repeating multi-dose 
pipette. 
iii- The tubes were covered with aluminum foil and briefly vortex mixed. 
Then the tubes were incubated in a water bath at 37°C for 15 minutes.       
Wash step I 
i- The assay tubes were removed from the water bath.  
ii- 500 µl diluted prolactins EIA wash Buffer was added to tubes at room 
temperature using repeating 500 µl multi-dose pipette, and briefly 
vortex – mixed.  
iii- The rack of tubes was placed onto a magnetic base for 5–10 minutes. 
All the tubes were in contact with the surface of the magnetic base 
until all magnetic particles had been sedimented. 
iv- The supernatant liquid was decanted from all tubes by inverting the 
separator over a sink (Keeping all tubes in contact with the magnetic 
base). Immediately the inverted separator was placed on absorbent 
paper and removed remaining droplets in tubes by gently tapping the 
tubes in the separator on the paper. 
v- The separator was returned to an upright position. 
vi- The rack of tubes was removed from the magnetic base. 
(b) Step II reaction: Labelled Antibody reaction: 
i- After removing the rack of tubes from the magnetic base, 250 µl 
diluted prolactin EIA Enzyme-labelled antibody was added at room 
temperature. 
ii-  The tubes were covered and briefly vortex-mixed and incubated in a 
waterbath at 37°C for 1 hour. 
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Wash step II (two washes): 
i- The rack of tubes was removed from the water bath. 
ii- 500 µl of diluted prolactin EIA wash buffer were added to the tubes 
and briefly vortex-mixed at room temperature. 
iii- The rack of tubes was placed onto a magnetic base for 5–10 minutes 
until all magnetic particles had been sedimented. 
iv- The supernatant liquid was decanted from all tubes and separator 
returned to the upright position. 
v- The rack of tubes was then removed from the magnetic base. 
vi- Steps (ii) to (v) were repeated. It was essential to wash the magnetic 
solid phase twice to remove all unbound labeled- antibody. 
(c) Colour Development step: 
i- 500 µl of substrate solution was added to all tubes at room 
temperature. 
ii- A substrate blank tube required for zeroing the colorimeter was 
included in this addition. 
iii- The tubes were covered with suitable film and briefly vortex- mixed. 
iv- The tubes were then transferred to 37°C waterbath for 30 minutes. 
v- The tubes were removed from the waterbath.  
vi- 1 ml of EIA stop Buffer was added to the tubes. 
vii- The tubes were stood in the magnetic separator for at least 10 
minutes. 
This sedimented all particles producing a clear solution for colour 
measurement. 
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(d) Optical Density Measurement: 
The optical density (OD) had been read at 550 nm within 24 hours of the 
completion of the assay using a photometer. 
2.2.2. Follicle stimulating Hormone estimation: 
The enzyme immunoassay (EIA) system was developed for the 
measurement of FSH in human serum or plasma. The concentration range 
covered by the standards is 0–200 IU/L by Immunometric (UK) Ltd. 
2.2.2.1.  FSH EIA Assay Procedure: 
All steps of FSH EIA procedure are similar to the steps of prolactin EIA 
procedure (2.2.1.1). 
2.2.3.  Luteinising Hormone estimation: 
The enzyme immunoassay (EIA) system was developed for the 
measurement of luteinising hormone (LH) in human serum or plasma. 
The concentration range covered by the standards is 0–150 IV/L (WHO IRP 
80/552) by immunometric (UK) ltd. 
 
2.2.3.1.  LH EIA Assay Procedure: 
All steps of LH EIA procedure are similar to the steps of prolactin EIA 
procedure (2.2.1.1). 
2.2.4.  Estradiol estimation:  
i- Principle:  
The estradiol EIA direct assay is of a limited competitive type. Specific 
agent is used to displace estradiol from binding proteins, thus making it 
available for antibody binding. 
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The estradiol in samples, controls or standards reacts with flouorescein 
labeled polyclonal antiestradiol antibody and then equilibrates with a fixed 
amount of alkaline phosphate labeled estradiol. 
An anti–fluorescein separate the estradiol/estradiol-antibody complex from 
unbound components by magnetic sedimentation. 
The magnetic particles are incubated with enzyme substrate solution for a 
fixed time and the reaction ended by addition of a stop buffer. The amount 
of colour produced is inversely proportional to the amount of estradiol 
present in the sample. 
The estradiol concentration of test samples is then interpolated from a 
calibration curve.         
ii- Estradiol EIA Assay Procedure:     
Samples were analyzed by the procedure described below carried in 
steps: 
      Step I (setting):  
• 150µl of standard and 150µl of sample were pipetted into labeled 
tubes using a manual 150µl pipette. 
•  200 µl of Estradiol Antibody were added to each of the standard and 
sample tubes using a 200 µl repeating multi-dose pipette at room 
temperature. 
• Tubes were covered and briefly vortex mixed. 
• The tubes were then incubated in a waterbath at 37°C for 20 minutes. 
Step II (Enzyme addition):  
• 200 µl of enzyme-labeled Estradiol was added to the tubes using a 
200µl repeating multi-dose pipette at room temperature.  
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• The assay tubes were covered with plastic, aluminum or other suitable 
film. After mixing the tubes were transferred to the water bath and 
incubated for 20 minutes. 
Step III:   
• 200 µl of separation reagent was added to the tubes (well shaken to 
ensure magnetic particles were well suspended). 
• The assay tubes were then covered and after mixing, the tubes were 
transferred to the waterbath and incubated for 5 minutes. 
Step IV: 
• The assay tubes were removed from the waterbath. 
• The rack of tubes was stood on the magnetic base for 5 minutes 
ensuring contact with the surface of the magnetic separator to 
sediment magnetic particles. 
•  The supernatant was decanted out of the tubes by inverting the 
separator over a sink (keeping all tubes in contact with the magnetic 
base). 
• The inverted separator was immediately placed on absorbent paper 
and remaining droplets of supernatant in the tubes were removed by 
gently tapping the tubes in the separator on the paper. 
• Separator was then retuned to an upright position. 
• The rack of tubes was removed from the magnetic base. 
Step V (washing):    
• 500 µl of diluted E2 EIA wash buffer was added to tubes and briefly 
vortex-mixed. 
• The rack of tubes was placed onto magnetic base for 5 minutes to 
sediment magnetic particles at room temperature. 
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• The supernatant liquid was decanted out of the tubes by the same 
procedure described in step IV and the separator was then returned to 
the upright position.  
• The rack of tubes was removed from the magnetic base. 
All these steps for washing were repeated one more time. It was essential 
that the magnetic solid phase was washed twice to remove all unbound 
enzyme label.  
Step VI (Colour development):    
• 500 µl of substrate solution was added to the tubes. A substrate blank 
tube was included. 
•  The assay tubes were covered with a suitable film and briefly vortex-
mixed. 
• The tubes were transferred to 37°C waterbath and incubated for 60 
minutes. 
• The tubes were removed from the waterbath. 
• 1 ml of EIA stop Buffer was added to tubes and briefly vortex mixed. 
• The rack of tubes was placed onto a magnetic base and stood on the 
magnetic base for at least 10 minutes. This sediments all particles 
producing a clear solution for colour measurement. 
Step VII  Optical density measurement : 
The optical density (OD) of tubes had been read within 24 hours of 
completion of the assay using suitable photometer at 550nm and 492 nm . 
Step VIII : Calculation of results :  
 OD 550 nm values had been used to calculate most results . 
The OD values can be processed using an appropriate automated calculation 
program . 
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2.2.5  Survey :  
A structured questionnaire was designed (Appendix 10). The aim and 
purpose of the questionnaire was fully explained to participants. It was also 
made clear that the information will be strictly confidential and only used for 
the research purpose. Consent of each participant in the questionnaire was 
obtained and the author thereafter filled and analyzed the questionnaire.  
 
2.2.6. Study duration and area: 
The investigations were carried out in the period extending from 12th March 
to 18th August 2005 in the Reproductive Health Care Centre in Khartoum. 
The selection of this centre was for two reasons:- 
1- The centre was ready to collaborate in this research by allowing the 
investigator to use their laboratory facilities. 
2- It is one of the leading fertility centers in the country and visited by 
many infertiles couples from different regions of Sudan. Part of this 
study was also carried out in Asia Hospital in Omdurman. 
  
2.2.7.  Statistical analysis Procedure:- 
Technique: 
Data generated was subjected to statistical Package for Social Sciences 
(SPSS). Means (± SD) were tested using t-test to calculate the difference 
between two groups or more (Mead,B. and Gurany,R.W.(1983)). 
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CHAPTER THREE 
Results 
3.1. Measurement of serum hormones: 
3.1.1 Serum prolactin levels: 
Table (1) shows the serum level of the prolactin of infertile females. They 
are grouped into three categories; moderately high, high and very high with 
reference to the level of hyperprolactinemia. The values upto 550mIU/L 
were related to normal,. The 1st group of 28 patients exhibited prolactin level 
of 551-799 mIU/L, 2nd twenty patients with prolactin value from 800 – 1244 
mIU/L, 3rd  group – twenty- two  ( n = 22) patients with prolactin value more 
than  1245 mIU/L.  
Serum prolactin mean levels of the three groups are highly significant 
compared to control mean ± SE of 146.93 ± 21.6 and P= 0.001 in 1st and 2nd 
groups. P=.000I in the 3rd  group  
Figure (4) illustrates the findings in table (1) serum prolactin level and the 
control of the three groups, it is clear that the serum prolactin levels in the 
three groups are higher than the control. 
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Table (1): Grouping of infertile female based on PRL levels 
Groups t-test of PRL 
No. of 
patients 
PRL level 
   (Mean ± SE) mIU/L 
P< 
G1 24.7144* 28        670.07±10.4* 0.01 
G2 21.9833** 20 959.0±27.5** 0.001 
G3 15.7251** 22 1679. 7±95.1*** 0.001 
control - 15 146.93±21.6 - 
Keys:- 
** = Highly significant 
G1= Group 1 Moderately high PRL level . 
G2= Group 2 high PRL level . 
G3= Group 3 Very high PRL level .  
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      Fig. (4): Prolactin levels in infertile patients and 
control
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3.1.2. Serum gonadotropin levels: 
The serum levels of FSH and LH for the three groups of hyperprolactinemic 
infertile females are shown in table (2) and illustrated in Figures (5) and (6) 
respectively. The mean values of FSH and LH were compared with mean 
values of FSH and LH in the control group. A consistent drop,  in the levels 
of both FSH and LH with increasing degree of hyperprolactinemia is 
observed. The drop is not significant for infertile females in goup 1 with 
moderately high prolactin level. However, it is significant (P< .01) for 2nd 
and 3rd group whose hyperprolactinemia is almost equal to or over 1000 
mlIU/L.  
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Table (2): Prolactin and gonadotropin in the three groups of  
infertile females 
Groups 
G1 
Mean ± SE 
G2 
Mean ± SE 
G3 
Mean ± SE 
Control Mean 
± SE 
PR
L 
(m
IU
/L
) 
670.07±10.4* 959.0±27.5** 1679.7±95.1*** 146.93±21.6 
FS
H
 
(m
IU
/m
l)  
12.81± 0.87 
 
 
11.00±0.16* 
 
8.00±0.14** 14.15±1.00 
LH
 
(m
IU
/m
l) 
8.92±1.09n.s 8.45±0.98* 6.5± 0.87** 10.33±0.45 
N 28 20 22 15 
 
Key: 
G3  = Group1 very high prolactin level  
G2  = Group2  high prolactin level 
G1  = Group3  moderately high  prolactin level 
N = Number of patients. 
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Key: 
 
C   = Control 
G1 = FSH level in group 1 
G2 = FSH level in group 2 
G3 = FSH level in group 3 
Fig. (5): FSH levels in infertile patients and control
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Fig. (6): LH levels in infertile patients and control
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Key: 
 
C   = Control 
G1 = LH level in group 1 
G2 = LH level in group 2 
G3 = LH level in group 3 
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3.1.3 Comparing gonadotropin with PRL levels: 
The differences in gonadotropins in relation to the degree of 
hyperprolactinemia in the three groups are shown in figure (7). It is evident 
that as the level of prolactin increases in these patients so drop the 
gonadotropins in a consistent manner. 
 
Fig. ( 7): Control Prolactin, FSH and LH Levels in Infertile Patients
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3.1.4. Menstrual cycle pattern in hyperprolactinemia: 
The 70 patients were grouped according to menses patterns into three 
groups, regular cycle (RC), irregular cycle (IC) and amenorrhoea (AM). This 
is shown in table (3) and illustrated in fig (8 ) A different pattern has 
emerged when hyperprolactinemic are grouped according to menses 
regularity. From the table it is clear that amenorrheaic patients were having 
the highest levels of FSH, LH and prolactin, the patients with regular cycle 
are having the lowest levels of gonadotropins and prolactin. 
Oligomenorrhoeic (irregular cycles) levels of these hormones were found to 
be medium between the two groups. The amenorrheaic patients represents 
more than half of the patients (55.7%), while patients with  regular and 
irregular cycle patterns represented 21.4% and 22.9% respectively. 
FSH is significantly lower in regular and irregular menses than it is in 
controls whereas it is significantly higher in amenorrheaic patients than in 
controls. This in fact stands in contradiction to pattern without consideration 
of menstrual cycle patterns. 
LH is also significantly higher in amenorrheaic patients than in controls. 
However, this hormone level in patients with regular and irregular cycles is 
closer to the control value. 
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Table (3) Levels of PRL, FSH and LH in patients with different 
menstrual cycle patterns: 
 
Hormones 
 
RC 
 
IC 
 
AM 
 
Control 
PRL 
Mean ± SE 
 
932.21±2.1* 
 
1038.6± 6.6* 
 
1412.63±9.7** 
 
146.93±21.6 
FSH 
Mean ± SE 
 
10.59±1.4** 
 
10.64±1.0** 
 
18.36±2.8** 
 
14.15±1.0 
LH 
Mean ± SE 
 
8.04±0.1* 
 
10.58±1.9 
 
16.60±2.0** 
 
10.33±0.7 
 
No. of patients 
 
15 
 
16 
 
39 
 
15 
 
P< .01 
Key: 
RC = Regular cycle 
IC = Irregular cycle 
AM = Amenorrhea 
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Fig. (8) Menstrual cycle patterns
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3.1.5 LH/FSH ratio:- 
Among the study group those who have had serum LH  higher than serum 
FSH were 15 with a percentage of 21.42% of the study population.  
3.1.6. Serum estradiol levels: 
It is clear that estradiol is significantly lower in infertile females compared 
to the control group with a mean ± SE of 29.20 ± 3.0 Pg/ml, P< 0.0001. 
 
3.1.7.  Measurement of esradiol (E2), PRL , FSH , and LH in infertile 
patients: 
The relationship between estrogen status gonadotropins and prolactin levels 
were investigated in some hyperprolactinemic patients. The mean values is 
presented in table (4) and figure (.9,10 and11). Table (1) in appendix shows 
detailed values. 
A complex pattern emerges from the data and careful interpretation is very 
much needed. 
 
Table (4): Estradiol, prolactin and gonadotropins in hyperprolacinemic 
infertile females:  
  
N 
Estradiol (pg/ml) 
Mean ± SE 
PRL (mIU/L) 
Mean ± SE 
LH (mIU/ml)  
Mean ± SE 
FSH (mIU/ml) 
Mean ± SE 
 
Control 
 
15 
 
29.2± 3.0 
 
146.93±21.6 
 
10.33±0.7 
 
14.15±1.0 
 
Patients 
 
30 
 
2.2433 ± 0.6 
 
1237.60  ± 99.1
 
 7.49 ± 1.8 
 
11.47 ± 2.8 
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Fig. (9): Prolactin and estradoil
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Fig . (10 ): LH and estradoil
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3.2 Questionnaire data analysis: 
Part of the study was carried out with a questionnaire constructed to obtain 
insight into the incidence of hyperprolactinemia regarding age, 
socioeconomic status, environmental and/or genetical factors and 
pathologies. The questionnaire was conducted in 70 patients who was 
diagnosed to be infertile due to high levels of prolactin, representing about 
18.5 of reported infertility in these clinics. 
 
3.2.1 Age: 
Of these 70 patients who have infertility due to high levels of prolactin, 23 
were in the age range 15 – 25 years, representing 32.9%, 34 patients were in 
26 – 35 yeas, representing 48.6% and 13 patients were in the age group 36 –  
45 years, representing 18.5% (Figure 12). Tables of the questionnaire 
included in the table 2 in  appendix. 
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All the patients have been married over 5 years. The detailed duration of 
marital life is shown in Figure (13). 
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Fig.12: Percent age groups of the patients
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Fig13 Marriage duration
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3.2.2 Environmental and genetical factors: 
Patients in the study were found to come predominantly from central (Sinar, 
WhiteNile and Gazira) and northern parts of the country beside Khartoum 
(Figure 14). 
A minor group of the patients are from the south, west and east. However 
residency over the past 5 years is not consistent with the original regions  of 
patients (Figure 15). In this respect, the author intend to look into tribal 
origins as well as residency if an interplay of genetical and environmental 
factors are to be considered. 
The questionnaire showed that about 25% of the patients have infertility 
incidence among relatives (Figure 16). 
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Fig. 14: Residential regions of the patients
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Fig.15: Area of residence during the last 5 years
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Fig. 16: Family history of infertility
Yes
25.71%
No
74.29%
 52
3.2.3.  Pathologic factors: 
Hyperprolactinemia was diagnosed after complaints of breast secretion 
(galactorrhea) in about 34.3%. However, 66.7% of the patients were without 
complaints. Examination of the medical history of the patients indicates that 
about 23% of them received medical treatment for their hyperprolactinemia. 
44% of the patients were actually on medications for other diseases when the 
present investigation was done (fig 17, 18, 19, 20). Patients with 
hypothyroidism accounted for 8.57% of the investigated group. 2.86% were 
found to be hypertensive and receiving treatment for their hypertension. No 
diabetic patients were among the study group. 
 
 
  
Fig . 17 : Drugs used by hyperprolactinemic infertile females 
Yes 
44.29% 
No 
55.71% 
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Fig. (18) Thyroid diseases
Yes
8.57%
No
91.43%
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19
Yes
2.86%
No
97.14%
Hypertensive patients . ( ): Fig 
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Fig. (20): Diabetic patients
Yes
0.00%
No
100.00%
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3.3 Incidence and prevalence of hyperprolactinemia in 
Sudanese female patients infertility: 
It was undertaken in this study to determine the incidence of 
hyperprolactinemia in a group referred infertile Sudanese female in the 
Reproductive Health Care Center (RHCC) in Khartoum. The investigation 
covered the period from 2001 to 2005, and in Asia Hospital for years 2004 – 
2005.( in table10,11 Appendix ). The choice of the duration was governed 
by data availability in the RHCC and the life time in Asia Hospital ( new 
centre). 
A slight but a steady increase in the incidence of hyperprolactinemia is 
observed. In 2001 hyperprolactinemic infertile females accounted for 14.32 
of all infertile females visiting the RHCC. In 2005 they accounted for 
18.35%.  A similar increment is also seen Asia Hospital record. 
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CHAPTER FOUR 
DISCUSSION 
4.1 Female infertility: 
Reproductive health is a state of complete physical, mental and social well-
being in all aspects relating to the reproductive system and to its functions 
and processes. Infertility is a world-wide problem affecting people of all 
communities, though the cause and magnitude may vary 
with geographical location and socio-economic status (Farley and Belesey 
1988).  
Infertility is a crippling problem to million of couples affected the world 
over. It is estimated that globally between 60-80 million couples suffer 
from infertility every year(World Health Organization 1996).  
The relationship between changes in prolactin, reproductive hormones and 
menstrual pattern in infertile females vary widely and there are geographic 
variations in the deferent cases of infertility. The ovarian sensitivity to 
prolactin is also extremely variable. 
Many fertility centers in Sudan are visited by many infertile couples 
including the Reproductive Health Care Centre in Khartoum, Asia Hospital 
for IV.F. in Omdurman and Sudan Centre for Fertility.  
4.1.1 Infertile patients with high levels of serum prolactin: 
Differences in PRL, FSH, LH and estradiol levels of Sudanese infertile 
females were revealed in this study when compared with controls. The 
following observation are evident and deserve consideration and discussion: 
     1) Serum PRL is statistically significantly higher in infertile Sudanese 
females (hyperprolactinemia). 
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     2) Serum FSH and LH are lower than the control in the three groups of 
infertile Sudanese females. 
3) FSH/LH ratio in the control group is almost one, while it is much less 
than one in 21.42% of the 70 patients of the infertile Sudanese 
females. 
In over two thirds of hyperprolactinemia patients did not suffer from 
galactorrhea, this is in a good agreement with previous finding (Rosato and 
Garofalo 2002) where galactorrhea appears in  30% of patients. 
Infertile patients with hyperprolactinemia are arbitrarily grouped into three 
categories according to the levels of serum prolactin. Significantly elevated 
serum prolactin in these groups of infertile Sudanese females is indicative of 
the role of prolactin in causation of infertility. This finding is in good 
agreement with previous findings (Homburg 2003). The second point which 
deserves consideration is that in the first and second groups mean levels of 
follicle stimulating hormone and Lutenizing hormone were lower but not 
significantly different compared to the control group. In the 3rd group the 
mean levels of follicle stimulating hormone and lutenizing hormone is 
significantly lower than the control groups. This also in good agreement 
with previous findings (Mohammed 1992), where it was suggested that high 
serum prolactin may inhabit FSH and LH secretion (Mohamed 1992; 
ML'Hermite et al., 1978). It was also suggested that the elevated prolactin 
not only suppress the pituitary gonadotropins secretion, but also disturb 
follicular development and luteal function in the ovary (Lino1997). 
Hyperprolactinemia may cause anovulation through:  
a.A reduction in granulosa cell number and FSH binding 
b. Inhibition of granulosa cell 17 estradiol production by interfering with 
FSH action. 
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c. Inadequate luteinization and reduced progesterone 
d.  The suppressive effects of prolactin on GnRH pulsatile release. 
Normal or low FSH or LH levels suggest a pituitary or hypothalamic 
abnormality (hypogonadotropic hypogonadism). Elevated follicle-
stimulating hormone (FSH) or luteinizing hormone (LH) levels suggest an 
ovarian abnormality (hypergonadotropic hypergonadism).  (Master-Humter 
and Heimen 2006). This may explain variation in gonadotropin levels in 
hyperprolactinemia. Hypothalamic amenorrhea is associated with 
abnormalities in gonadotropin-releasing hormone (GnRH) secretion and 
disruption of the hypothalamic-pituitary-ovarian axis. The condition often is 
caused by excessive weight loss, exercise, or stress (Mitan 2004).  
The presence of elevated serum lutenizing hormones (LH) with suppressed 
follicle stimulating hormone (FSH) resulting in an increase LH/FSH ratio 
has been observed in 21.42% of the 70 patients under study.  This in fact is a 
higher incidence than that reported in the literature which is 17% (Luciano et 
al.,1984).  
Increased LH/FSH ratio is suggestive of polycystic ovary syndrome (PCO) 
which associated with hyperprolactinemia may be responsible for infertility. 
This is also in good agreement with previous reports (Owecki and Sowinki 
2004). where it was suggested that functional hyperprolactinemia in PCO 
may be remarkably high. 
 
4.2 Hyperprolactinemia and menstrual patterns: 
Patients in this study were further categorized on bases of menstrual cycle 
patterns as regular, irregular or completely missed menses i.e. amenorrhea.  
There are unrevealed differences with regard to the levels of gonadotropins 
in relation to hyperprolactinemia degree affecting ovulation. These 
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differences are manifested in different menses patterns varying from 
irregular to amenorrhoea. 
Amenorrhoeic patients with significantly elevated of PRL mean levels group 
and elevated means of gonadotropins hormones may indicate ovarian failure. 
In this case the amenorrhoea may be due to compounded factors including 
ovarian failure on one hand and hyperprolactinemia on the other (Master-
Hunter and Heiman 2006).  
Regularly menstruating female exhibit lower prolactin levels compared to 
amenorrhoeaic patients. Hyperprolactinemia has been reported to result in 
short luteal phase (Elsheiksh et al.,1984). Prolactin has been found to be 
persistently elevated not only in many of the subjects with menstrual 
abnormalities but also in some of those with apparently normal menstrual 
cycles. This depends on the underlying cause of hyperprolactinemia as well 
as the severity of the condition. The incidence of hyperprolactinemia was, 
however, much higher among women with amenorrhea than among those 
with normal cycle or with patients with oligomenorrhea showing an 
intermediate frequency. Serum PRL in the present study was found to be 
significantly higher in amenorrhoea as compared with normal menses, while 
the level in oligomenorrhoea was found to be intermediate between 
amenorrhoea and regular cycles, which is consistent with other authors 
findings (Bahamondes et al.,1985). 
However, it appears paradoxical to see a different patterns with 
gonadotropins to the one reported earlier without considerations of menses 
regularity. This paradox may be resolved if one considers the amenorrhoeaic 
patients with the highest PRL levels. The gonadotropins are expected to 
peak during mid-cycle during the ovulatory phase and return to lower than 
baseline levels of follicular phase. When PRL is extremely high it affects the 
–ve feedback loop operating on gonadotropins through an appreciably high 
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levels of oestrogen. But high PRL suppressed oestrogen production 
consequently gonadotropin will remain high. This explanation is offered 
because all estimations were carried on samples withdrawn during follicular 
phase. This explanation is quite plausible in the light of the present results 
where hyperprolactinemia in amenorrhoeaic patients has shown to exist with 
significantly low oestrogen and elevated LH and FSH. An alternative 
explanation could be premature ovarian failure. 
Premature ovarian failure (POF) or is defined as consisting of the triad of 
amenorrhea, hypergonadotropinism, and hypoestrogenism in women under 
the age of 40 years. Circulating gonadotropin levels rise whenever ovarian 
failure occurs because of decreased negative estrogen feedback to the 
hypothalamic-pituitary unit. Gonadotropin levels sometimes increase even in 
the presence of viable oocytes, but the explanation for such increases is 
unclear.  The peculiar finding in this context is the hyperprolactinemia. 
It has been attempted to check the levels in ovulatry or luteal phases 
particularly in regular cycles and irregular cycles to see if different patterns 
emerge that are comparable to the ammendrrheaic situation but that was not 
practical.  
Hypergonadotropic hypergonadism (elevated FSH and LH levels) in patients 
with primary amenorrhea is caused by gonadal dysgenesis or premature 
ovarian failure. Turner's syndrome (45,XO karyotype) is the most common 
form of female gonadal dysgenesis (Master-Hunter and Heiman 2006). 
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4.3 Serum estradiol levels: 
In this study significantly lower levels of estradiol in patients with 
hyperprolactinemia has been noticed. It suggests that hyperprolactinemia 
may lead to hypostrogenism. This is supported by reports pointing to the fact 
that prolactinoma is a risk for osteoporosis (Adler et al., 1998) a condition 
well known as a consequence of lack of oestrogens. When patients with 
hyperprolactinemia are not treated, a number of ramifications can result the 
most significant of which is ostoporosis. Evidence-based analysis shows that 
bone mineralization also can be affected by such problems as gonadal 
dysgenesis and possibly adrenal dysfunction. The hypoestrogenism 
associated with hyperprolactinemia is commonly assumed to be a potential 
cause of osteopenia in premenopausal women, just as decreased estrogen is 
associated with bone loss following menopause (Sanfilippo1999). 
 4.4.  Questionnaire data analysis: 
4.4.1. Age : 
Over 80% of the patients are within the best period of reproductivity. 
Regarding the age it is not surprising to find almost 50% of the infertile 
patients with hyperprolactinemia  to be between 25-35 years. This perhaps  
is the age females will be very much concerned about their reproductive 
health. Although hyperprolactinemia could very much be encountered in a 
much younger age, complaints are not clinically presented due to a number 
of factors. Among these is lack of symptoms such as galactorrhea and 
amenorrhoea. Another reason is the social stigma of sending young 
unmarried females to seek medical advice in obstetric and gynaecology 
clinics. This in fact will result in unfavourable situation later in life because 
hyperprolactinemia has adverse complications such as pre-menopausal  
osteoporosis optical nerve disorders (Kaye 1996; Valdemarsson 2004). 
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4.4.2. Geographical and ethnic distribution: 
The majority of the patients are from Central and Northern parts of the 
country. Whether this is a true indicator or not can  not be concluded from 
such a sstudy. Only a cohort study of a bigger size and a longer duration can 
give a faithful conclusion. However, this does not rule  out the importance of 
a pilot study like the present one.  
That a minor group is from the south, west and east of Sudan may be 
explained by the remotenss of these areas, the socioeconomic status 
(travelling and lodging expenses etc..), health awareness and educational 
level of the patients. Added to this the cultural taboos that encircle infertility. 
In the developing countries, the incidence of induced-infertility is 
relatively high; being higher among the less educated people 
of low economic status. On the other hand, in developed countries or among 
individuals of higher socio-economic status, the main causes of infertility are 
genetical, anatomical, or endocrinological (Farley and Belsey 1988). 
 
4.4.3. Environmental and genetical factors: 
It is perhaps worth to follow the prevalence of hyperprolactinemia infertility 
in certain regions of the country namely north and central Sudan with further 
studies to investigate the underling causes and if these are genetical, 
environmental or both. A genetical factor may be considered particularly if 
consanguity marriages are not overlooked; which is a wide spread practice in 
Sudan and this reflected in this study by a 25% incidence of infertility 
among relatives of the patients invetigated. Underlying genetical causes are 
not well established in female infertility as they are in male infertility. 
Turner's syndrome (45,XO karyotype) is the most common form of female 
gonadal dysgenesis(Master-Hunter and Heiman 2006). However, other 
genetical causes may involve 
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Mutation of specific genes of enzymes, receptors, hormone response 
elements and/or G-proteins. 
Environmental estrogens (xenoestrogens) are a diverse group of chemicals 
that mimic estrogenic actions. Bisphenol A (BPA), a monomer of plastics 
used in many consumer products, has estrogenic activity in vitro. The 
pituitary lactotroph is a well established estrogen-responsive cell. 
BPA is found to mimic estradiol in inducing hyperprolactinemia in 
genetically predisposed rats and that  the in vivo action of estradiol and BPA 
in F344 rats is mediated, at least in part, by increasing PRL regulating factor 
activity in the posterior pituitary (Rosemary et al., 1997). BPA appears to 
regulate transcription through an ERE, suggesting that it binds to estrogen 
receptors in both the anterior and posterior pituitaries. The possibility that 
BPA and other xenoestrogens have adverse effects on the neuroendocrine 
axis in susceptible human subpopulations is not excluded (Rosemary et al., 
1997). 
While it has long been known that female fertility is impaired by oestrogen 
exposure, it is unclear whether environmental pollutants with weak 
oestrogenic effects are sufficiently potent and prevalent to have biological 
effects in humans (Joffe 2003). 
Chemicals in tobacco smoke can alter important reproductive hormones 
(such as estrogen, progesterone, and testosterone)(Florack et al., 1994). 
 
4.4.4. Associated Patholigies: 
Over 11% on medications are  either receiving antihypertensive drugs or 
being treated for hypothyroidism. Another important consideration is that 
mild to moderately raised prolactin levels often present as one of the earliest 
signs of an impending or existing hypothyroid state. In women 
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hypothyroidism is most often due to an autoimmune process (Hashimoto’s 
Disease).   
Perhaps more significant than the presence of a raised plasma prolactin 
level, is the reason for this having occurred in the first place. Raised plasma 
prolactin levels may occur as a consequence of a prolactin producing 
pituitary tumor (adenoma) or other intracranial lesions. In addition, the use 
of certain drugs: (tranquilizers, antihypertensives, antidepressants, thiazides 
and narcotics) can elevate the blood prolactin level.  Thus, it is possible that 
in some of the studied patients the underlying cause of their 
hyperprolactinemia is the use of certain drugs. 
The sample size in this study is small and can barely give a thorough 
information pertinent to which cause is predominant over others. 
A cohort study is likely to validate this finding which will need time, 
resources and collaboration of investigators from different disciplines. 
4.4.5. The incidence of hyperprolactinemia in Sudanese females: 
The prevalence and incidence of hyperprolactinemia bearing in mind all the 
different causes contributing to its precipitation seems to be on the rise in 
Sudanese females of child-bearing age. The % of hyperprolactinemic 
patients seen in the RHCC between 2001- 2005 went up from 14.3% to 
18.3%. whether this steady increase is a valid observation can not be 
ascertained here; further investigations are needed taking into consideration 
a bigger sample size and perhaps a longer duration ( if a particular persisting 
factor is an underling cause).  
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Conclusions and recommendations: 
It is concluded from the present investigation that hyprerprolactinemia 
though not of high incidence ( less than 18%) is one of the primary causes of 
infertility in Sudan. It is often accompanied by decreased gonadotropins. 
In accordance with other studies, hyprerprolactinemia is found to be 
responsible for menstrual cycle abnormalities with the dominance of 
anovulation ( >50%). However, in some patients menstrual cycles are not 
affected. It is worthwhile noting that this situation is only seen when 
hyprerprolactinemia is not severe ( moderately high level < 800 µ IU/L).  
Hypoestrogenism is also found in these patients confirming the idea that 
untreated hyprerprolactinemia precipitate osteoporosis, presumably due to 
the low estrogen levels rather than due to high prolactin levels. 
An interplay of hormonal milieu seems to govern the outcome of the 
condition in infertile females. 
 
Recommendations: 
•   More investigations are needed to resolve the complexity of the 
issue. 
•  Attention should be given to the infertility problem in the country in a 
coordinated manner. 
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•  Socioeconomic, environmental and genetical factors as underlying 
causes of infertility should be addressed and investigated through 
multidisciplinary teams. 
•  Cohort studies should be encouraged and facilitated through 
governmental bodies and the  private sector, which will benefit future 
work and planning regarding reproductive health. 
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1. Appendices: 
Table (1) Measurement of esradiol (E2) and PRL , FSH , and LH in patients 
  
E2(pg/ml)LH(mIU)/mlFSH(mIU/ml)PRL(mIU/L) 
0.1254.60.81208 
0.82.03.2 2228 
0.6250.46.81175 
0.1254.97.001528 
0.15.71.81368 
0.251.23.21402 
0.10.32.22800 
0.3753.35.81727 
0.251.55.4986 
0.250.80.91254 
8.50.31.22600 
0.41.93.51077 
1.32.61.61147 
2.40.71.7929 
1.000.31.6648 
1.71.001.61425 
6.13.94.91246 
3.40.77.7577 
2.005.62.6647 
2.70.61.00800 
3.51.004.41317 
1.70.20.51084 
0.10.20.31104 
2.80.65.41211 
5.62.12.00961 
0.52.66.4954 
0.23.81.11678 
1.60.85.1625 
0.10.90.7958 
7.002.94.00763 
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 Table 2: Ages of patients (years) 
Age groups Frequency % 
15-25 23 32.86 
26-35 34 48.57 
36-45 13 18.57 
Total 70 100% 
Table 3: Marriage duration (years) 
Years Frequency % 
About 5 36 51.42 
6-10 23 32.86 
11-15 8 11.43 
Over 15 3 4.29 
Total 70 100% 
 
Table (4): Presence and history of other types of disease in  
  hyperprolactinemic patients 
 
Diseases No. of patients % 
Hypertension  2 2.86% 
Thyroid 6 8.57% 
Diabetes 0 0 
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Table 5 : Menstrual cycle pattern  
 Frequency % 
Regular 15 21.4 
Irregular 16 22.9 
Amenorrhea 39 55.7 
Total 70 100% 
 
 
Table 6: Drugs used by hyperprolactinemia infertile female 
 Frequency % 
Yes 31 44.29 
No 39 55.71 
Total 70 100% 
 
Table 7: Family history of infertility 
 Frequency % 
Yes 18 25.71 
No 52 74.29 
Total 70 100% 
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Table 8: Geographical distribution of patients 
Origin Frequency % 
Northern of Sudan 16 22.86 
Eastern of Sudan 4 5.71 
Western of Sudan 7 10.00 
Southern of Sudan 3 4.29 
Khartoum 19 27.14 
Central of Sudan 21 30.00 
Total 70 100% 
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Table 9: Area of residence during the last five years 
Residence Frequency % 
Northern of Sudan 12 17.15 
Eastern of Sudan 4 5.71 
Western of Sudan 5 7.14 
Southern of Sudan 0.0 0.0 
Khartoum 28 40.00 
Central of Sudan 21 30.00 
Total 70 100% 
 
 
Table (10): The incidence of hyperprolactinemia in Sudanese female 
patients infertility in reproductive health care center (2001 – 2005) 
 
Hormone Year No. of patients High level (abnormalities) % 
PRL 2001 998 143 14.32 
FSH “ 1051 241 22.93 
LH “ 1043 313 30.00 
PRL 2002 1202 174 14.44 
FSH “ 1130 245 21.68 
LH “ 987 240 24.31 
PRL 2003 935 141 15.08 
FSH “ 1384 303 21.89 
LH “ 1329 258 26.93 
PRL 2004 1472 239 16.236 
FSH “ 1730 412 23.82 
LH “ 1699 482 28.36 
PRL 2005 975 179 18.35 
FSH “ 941 236 25.07 
LH “ 925 303 32.75 
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Table (11): The incidence of hyperprolactinemia in Sudanese female 
patients infertility in Asia Hospital. (2001 – 2005) 
 
Hormone Year No. of 
patients 
High level 
(abnormalities) 
% 
PRL 2004 29 5 17.24 
FSH “ 32 8 25.00 
LH “ 23 5 21.73 
PRL 2005 172 32 18.60 
FSH “ 165 43 26.06 
LH “ 85 25 29.41 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
